More recent molecular profiling efforts have identified two important ACC subtypes: a more aggressive ACC-I defined by activating Notch pathway alterations and MYC amplification, and the more common ACC-II which demonstrates TP63 overexpression yielding a more indolent phenotype (11, 12). The gene discussed is TP63; the disease is adrenal cortex carcinoma.